Phase II, multi-center, open-label, single-arm clinical trial ...

A phase II clinical trial assesses mycophenolate mofetil's efficacy and safety in 27 patients with high-grade locally advanced or metastatic osteosarcoma. Primary endpoint: progression-free survival at 16 weeks. Secondary endpoints include overall survival, response rate, safety, pharmacokinetics, biomarkers, pain score, and quality of life.